JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2026, 75(1):62-64

Fixní kombinace antihypertenziv, adherence a rizika záměny v klinické praxi

PharmDr. Josef Suchopár, Mgr. ©těpán Suchopár
DrugAgency, Praha

Published: March 13, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Suchopár J, Suchopár ©. Fixní kombinace antihypertenziv, adherence a rizika záměny v klinické praxi. Čes. slov. farm. 2026;75(1):62-64.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 13.3.2027

    References

    1. Williams B, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39(33):3021-3104. Go to original source... Go to PubMed...
    2. Mancia G, et al. 2023 ESH Guidelines for the management of arterial hypertension. J Hypertens 2023;41(12):1874-2071. Go to original source... Go to PubMed...
    3. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc 2011;86(4):304-314. Go to original source... Go to PubMed...
    4. Wei Q, et al. Medication adherence with fixed-dose versus free-equivalent combination therapies: systematic review and meta-analysis. Front Pharmacol 2023;14:1156081. Go to original source... Go to PubMed...
    5. Chowdhury R, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013;34(38):2940-2948. Go to original source... Go to PubMed...
    6. Ho CT, et al. Clinical outcomes in hypertensive patients treated with a single-pill fixed-dose combination of renin-angiotensin system inhibitor and thiazide diuretic. J Clin Hypertens (Greenwich) 2018;20(12):1731-1738. Go to original source... Go to PubMed...
    7. Gupta P, et al. Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. Hypertension 2017a;70(5):1042-1048. Go to original source... Go to PubMed...
    8. Gupta P, et al. Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension 2017b;69(6):1113-1120. Go to original source... Go to PubMed...
    9. Gupta AK, et al. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55:99-407. Go to original source... Go to PubMed...
    10. Snyman JR, et al. A real-world analysis of outcomes and healthcare costs of patients on perindopril/indapamide/amlodipine single-pill vs. multiple-pill combination in Italy. J Hypertens 2024;42(1):136-142. Go to original source... Go to PubMed...
    11. Wolf J, et al. Real-world analysis exploring the association between anti-hypertensive therapy with perindopril-based single-pill combinations (SPC) and cardiovascular outcomes and all-cause mortality in Italy, Eur Heart J 2024;45(Suppl. 1):ehae666.2585. Go to original source...
    12. Levy P, et al. Cost-effectiveness analysis comparing single-pill combination of perindopril/amlodipine/indapamide to the free equivalent combination in patients with hypertension from an Italian national health system perspective. Expert Rev Pharmacoecon Outcomes Res 2024;24(8):967-975. Go to original source... Go to PubMed...
    13. Masi S, et al. A Retrospective Observational Real-Word Analysis of the Adherence, Healthcare Resource Consumption and Costs in Patients Treated with Bisoprolol/Perindopril as Single-Pill or Free Combination. Adv Ther 2024;41(1):182-197. Go to original source... Go to PubMed...
    14. Colloca L, Miller FG. The nocebo effect and its relevance for clinical practice. Psychosom Med 2011;73(7):598-603. Go to original source... Go to PubMed...
    15. Kesselheim AS, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA Intern Med 2016; 176(12):1826-1833. Go to original source... Go to PubMed...
    16. Corrao G, Parodi A, Nicotra F, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011;29(3):610-618. Go to original source... Go to PubMed...
    17. Weeda ER, et al. The impact of non-medical switching among ambulatory patients: an updated systematic literature review. J Market Access Health Policy 2019;7(1):1678563. Go to original source... Go to PubMed...
    18. Coleman C, et al. Impact of non-medical switching of prescription medications on health outcomes: an e-survey of high-volume physician providers. J Market Access Health Policy. 2020;8:1829883. Go to original source... Go to PubMed...
    19. Straka RJ, et al. Potential Clinical and Economic Impact of Switching Branded Medications to Generics. Am J Ther 2017;24(3):e278-e289. Go to original source... Go to PubMed...
    20. Vasan RS, et al. Hypertension-Mediated Organ Damage: Prevalence, Correlates, and Prognosis in the Community. Hypertension 2022;79(3):505-515. Go to original source... Go to PubMed...
    21. Vrijens B, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008;336(7653):1114-1117. Go to original source... Go to PubMed...
    22. Colombo GL, et al. Impact of substitution among generic drugs on persistence and adherence: A retrospective claims data study from 2 Local Healthcare Units in the Lombardy Region of Italy. Atheroscler Suppl 2016;21:1-8. Go to original source... Go to PubMed...
    23. Burnier M, Egan BM. Adherence in hypertension. Circ Res 2019;124(7):1124-1140. Go to original source... Go to PubMed...
    24. Tinetti ME, et al. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med 2014;174(4):588-595. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.